Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs

OBJECTIVES: Biological disease-modifying antirheumatic drugs (bDMARDs) have shown diminished clinical response following an inadequate response (IR) to ≥1 previous bDMARD. Here, tofacitinib was compared with placebo in patients with an IR to conventional synthetic DMARDs (csDMARDs; bDMARD-naive) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Charles-Schoeman, Christina, Burmester, Gerd, Nash, Peter, Zerbini, Cristiano A F, Soma, Koshika, Kwok, Kenneth, Hendrikx, Thijs, Bananis, Eustratios, Fleischmann, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941182/
https://www.ncbi.nlm.nih.gov/pubmed/26275429
http://dx.doi.org/10.1136/annrheumdis-2014-207178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941182/
https://www.ncbi.nlm.nih.gov/pubmed/26275429
http://dx.doi.org/10.1136/annrheumdis-2014-207178

Ejemplares similares